West Pharmaceutical Services, Inc. Q3 FY2025 earnings call

Key Points

• New Appointments: New CFO Bob McMahon joined in August, and new CTO [Davis matter] joined in August to accelerate innovation and new product introductions.
• Q3 Financial Results: Revenues $805 million, up 5% organically; adjusted operating margins 21.1%; adjusted EPS $1.96, up 6% year-over-year. Increased guidance for 2025.
• Proprietary Products Segment: HVP components revenue up 5.1% organically, driven by GLP-1 elastomers, biologics, and HVP upgrades. HVP Delivery Device revenues declined, but Standard Products grew. Contract Manufacturing Segment: Revenues up 4.9% organically, with activities around site consolidation and new business discussions.
• Operational Progress: Made progress hiring and training employees at HVP manufacturing site in Germany to expand capacity; ramping production in Dublin for obesity market and drug handling business.

Proprietary Products Segment

• Revenues: $648 million, up 5.1% organically. HVP components (largest and most profitable business) saw revenues up 13% organically, driven by GLP-1 elastomers (9% of total company sales), biologics (ordering trends normalizing), and HVP upgrades including Annex 1 (375 ongoing projects). HVP Delivery Device revenues declined compared to prior year, mainly due to a $19 million incentive payment from the prior year. Standard Products increased 3.6% organically.
• Contract Manufacturing Segment: Delivered revenues of $157 million, growing 4.9% organically. Utilizing Arizona CTM footprint to consolidate operations, expecting second CGM contract to conclude by end of Q2 2026, with promising discussions for future business. Dublin site ramping production of delivery devices for obesity market and validating equipment for drug handling business in early 2026.

Segment Performance Breakdown: Proprietary Products accounted for a significant portion, with HVP components being the largest contributor, and Contract Manufacturing showing steady growth.

Guidance

• Increased full-year 2025 revenue guidance to $3.06 billion to $3.07 billion (reported growth 5.8% to 6.1%, organic growth 3.75% to 4%).
• Increased full-year adjusted EPS guidance to $7.06 to $7.11 (year-over-year growth 4.6% to 5.3%).
• Fourth quarter 2025 revenue expected to be $790 million to $800 million (reported increase 5.5% to 6.8%, organic increase 1% to 2.3%).
• Anticipate mitigating more than half of tariff-related costs in 2025 and fully mitigating in 2026.
• HPV components business expected to lead growth with multiyear drivers like GLP-1s and HVP upgrades; CGM contract headwind in second half of 2026, with plans to refill space with higher-margin business; Dublin drug handling expected to add ~$20 million in revenue in 2026.

Risks

• Market dynamics and contract timings: Uncertainties around end markets and contract renewals/exits, including the transition of CGM contract and refilling space in 2026.
• Tariff-related risks: Impact of pharma tariffs and MFN policies on customer investment decisions, though efforts are underway to mitigate costs.
• Execution risks: Ensuring successful implementation of automation, capacity expansions, and new product introductions as planned.

Q: Congrats on the quarter. As you think about your long-term construct of 7% to 9% growth, are we heading there in 2026 in your opinion in terms of the momentum you're citing here in 3Q?

A: Yes, key drivers like HVP components with double-digit growth potential from biologics, biosimilars, GLP-1s, and Annex 1 lay the foundation. Bob McMahon added that they feel good about long-term growth despite puts and takes of contracts.

Q: The HPV components, as you said, a big part of the story. Really good growth in 2Q, continued that in the third quarter. Obviously, on GLP-1 and Annex 1 part of that. But could you talk about the sustainability of that being over double digits? And then on the margin comment you made, Bob, about expanding margins next year. Can you talk about the new pieces of that between gross margin and volume leverage or your cost actions?

A: Eric Green mentioned order patterns normalizing, bioprocessing space as a key indicator, and pipeline of new drug approvals. Bob McMahon noted HVP components driving margin improvement through investments, efficiency gains, and favorable mix of higher-value products.

Q: Maybe one quick one on the CDM contract. It sounds like -- kind of the exited mid-'26. I appreciate the commentary there, Bob, on the $40 million headwind. I guess in terms of the visibility and fulfilling that with high-margin business, it sounds like -- what are the conversations there? What would the timing look like in terms of the backfill? How big of a gap would there be? And then maybe secondarily, just following up on Mike's question there, Bob, I know you spent a lot of time thinking about the margin opportunity here, where there's opportunities, whether it's footprint, higher utilization when you dug into the company here and look at the margin opportunity, can you just talk about some of that long-term stuff that you see and what opportunity you see on the margin, not only the mix to high value but also just more efficient operations?

A: Eric Green said there are late-stage discussions with customers for replacing CGM business, expecting healthier economics. Bob McMahon talked about optimizing footprint for local customers and long-term efficiency gains through footprint consolidation and supply network optimization.

Q: Guys, congrats on the print and welcome, Bob. So Eric and Bob, I had a 2-parter for you. First, I'm curious on high-level headwinds and tailwinds to high-value components in 2026 as you see it today. As I think about it, I see a few tailwinds. One is that you're comping the destock, especially in the first half. Second, you have GLP-1s growing off of a larger base. Third, Annex 1 is accelerating following the uptick in project growth through 2025. And then lastly, you have this unique one-off customer situation that I think was about 150 basis point headwind to 25%, but should benefit $26 million. So wrapping up on this first one, is there anything else I should be thinking about as a headwind on the other side or anything I'm missing? And then the second question, zooming in on one of those on GLP-1 elastomer growth, it was mid-single-digit percent of sales in 2024, and now it's been climbing pretty steadily to now about 9% of total revs. That implies a pretty healthy growth for GLP-1s in 2025. Is it right to think it's more than like 50% growth? And if so, what's causing that, should we expect sustained over 20% growth over the next few years?

A: Eric Green discussed tailwinds from biologics, biosimilars, GLP-1s, and Annex 1, with some timing considerations for new drug approvals. Robert McMahon confirmed GLP-1 growth aligning with end market growth and underlying market dynamics.

Q: Thank you and Bob, you might have addressed my question right there, but I have a follow-up on GLP-1. It does seem like from the script data for Novo and Lilly that you're growing a lot faster than the market is growing. I wonder if there's a way to reconcile that. Could there be a compound or element here? Is it the clinical trial participation you alluded to? Any thoughts would be appreciated.

A: Eric Green explained that growth is broader than just script data, including vial needs, pipeline of new molecules, generics support, and multiple geographies.

Q: Good morning everyone, and first, I appreciate the increase detail and transparency on some of the disclosures this quarter. So a 2-parter for me. One, I just wanted to follow up on Annex 1. There were some updates earlier this year. And just curious how that's impacting customer decision-making and some of the conversions. And if that's been a catalyst for some of the acceleration we're seeing. And then part 2 earlier in the prepared remarks, you talked about liquid handling in Dublin, being about a $20 million opportunity, plus or minus. Is that sort of the peak opportunity? Or is there room for growth there in that facility beyond 2026?

A: Eric Green said Annex 1 is driving customer decision-making with EU regulator requirements, and there's significant market opportunity. Robert McMahon noted the $20 million is a ramp-up stage with room for growth beyond 2026 as utilization increases.

Q: Great. I echo the appreciation on the transparency, and I also welcome, Bob. I guess I want to just follow up on the -- just on the gross margin, really strong this quarter. Just curious if you guys are actually seeing, and I think this has been part of the team too, just an improvement in mix within HVP and getting more towards the -- up and to the right until the NovaPure and higher-margin HVP components. Are you seeing that dynamic continue as well?

A: Robert McMahon said gross margin improvement is due to HVP component investments, capacity utilization, higher-value product mix, cost reduction, and efficiency gains, with multiyear opportunities in these areas.

Q: Two quick topics I want to touch on. One is just a question on Q4 guidance and then one is on really visibility heading into next year. So on the fourth quarter, I want to confirm that you essentially bumped up guidance by the magnitude of the revenue beat. And if so, were there any timing dynamics in the third quarter that held you back from bumping up guidance more? Or was this just trying to be conservative in a period of continued uncertainty. So that's the first topic. The second is risk and visibility as a topic. So part of the attraction for a long time of West for investors has been that this has been a great sleep at night story, a steady compounder last year, with that in mind, I think the company and certainly the investment community were surprised by the roll-off of the incentive payments and drug delivery and also the changes in contract manufacturing. How would you characterize anything resembling that category of risk heading into year-end? I would guess you feel pretty good about it, but I just want to give你 an opportunity to kind of tell us where we should all feel better about this getting back to be in the old West again?

A: Robert McMahon said Q4 guidance bump is not due to timing dynamics but prudence, and Eric Green emphasized improving visibility through better market engagement and risk reduction.

Q: Just one on delivery license, relatively flat year-over-year, excluding the incentive fee. And I think you highlighted some improving economics ahead of the automated line coming on in 2026. So, can you just highlight some of the various aspects driving performance during the quarter and the variables that you're seeing on the top line of margins as well?

A: Eric Green discussed progress in driving down costs, improving efficiencies, and validating automation for SmartDose, with Robert McMahon adding that sequential improvements in delivery devices are on track and there's more room for margin improvement.

Q: Kind of a 2-part question around your manufacturing network. So after a couple of years of pressure on free cash flow and obviously an elevated CapEx spend for you, you've had a significant improvement in free cash this year as CapEx has normalized down to around 9%. So Bob, you referred a couple of times the opportunity for network optimization, but there's then the balance of obviously customers thinking about regionalization of manufacturing, some of the policy dynamics and obviously, still significant investment in HVP. So just as you think about maybe that balance of network optimization versus making sure you have capacity available for customers. But how are you thinking about the levels of CapEx needed to support growth, that'd be the first part. The second part is there's been a number of recent headlines around pharma tariffs and MFN. And I realize your business is tied to commercial volumes, not necessarily earlier-stage R&D how tuned in are your customers to those headlines in terms of influencing investment decisions versus sort of -- the train has left the station in terms of realization of their manufacturing.

A: Eric Green talked about CapEx focused on high-value product components with global centers of excellence, and Robert McMahon noted customers are engaged in discussions about tariff impacts, with efforts to support customers through global network leverage and tech transfers.

Q: I had another question on Annex 1. So talk about 2% contribution this year from Annex 1 projects. Can you break down how that split between those projects that are in a development or validation phase versus switches that have already been put in place and sort of hitting what I would call commercial production?

A: Eric Green said less than 40% of Annex 1 projects have converted to revenues, with project timelines varying from 3-4 quarters to 6-8 quarters depending on project scale and customer conversion speed.

Q: Just wanted to ask here about the capital allocation. The first one of the hat tip to the transparency on the -- and the deck is beautiful. So given that you guys have like a pristine balance sheet right now, producing a lot of cash margins going the right way. Free cash flow seems to be picking back up. So update us on your capital allocation priorities, favoritism towards maybe a repo versus more bolt-on M&A?

A: Robert McMahon said they are working on defining a capital policy, with a focus on using cash flows to drive business growth, and stay tuned for further details on capital allocation priorities.